home

epstein-data
Research ▼
🔍 SearchFull-text document search 🤖 Ask AIAI research assistant 🔎 Evidence MapFBI serial resolution 📷 Reverse Image SearchCLIP + face across 614K images 🧑 Find Face BETASearch 29K faces by photo 💻 Run Your OwnDownload & search locally
Explore ▼
📚 Full Text Corpus1.39M docs, 2.77M pages 🌎 Global Heatmap145 countries mentioned 📈 Coverage MapWhat's here 🌌 AtlasSemantic map · 1.29M docs ⚖ Cases53 federal & state cases · per-case briefings 🎤 DepositionsTranscribed audio & video 💬 Hear from the SurvivorsSurvivors in their own words 📖 Cover to Cover-Up24-hour public reading, synced to the video ✉ Wolff–Epstein Emails2,009 messages · 2009–2019
📷 Images92K analyzed photographs 🔍 Multi-DB SearchSearch all databases individually 🗃 All Databases14 searchable databases
Entities Reports
News ▼
📰 NewsCoverage & reporting ⚖ Justice MonitorArrests, charges, lawsuits, firings
Source ▼
🏛 DOJ ProductionOfficial EFTA disclosures 📜 EFTA Law TextPublic Law 119-38 📁 Source Data (GitHub)Open source databases
🌐 Community ResourcesCurated external projects ✉ ContactGeneral · privacy · DMCA · press
❤️ Donate 🎧 Podcast

Research

🔍 Search Documents 🤖 Ask AI 🔎 Evidence Map 📷 Reverse Image Search 🧑 Find Face BETA 💻 Run Your Own Investigator

Explore

📚 Full Text Corpus 🌎 Global Heatmap 📈 Coverage Map 🌌 Atlas ⚖ Cases 🎤 Depositions 💬 Hear from the Survivors 📖 Cover to Cover-Up ✉ Wolff–Epstein Emails 📷 Images 🔍 Multi-DB Search 🗃 All Databases

Entities

👥 Entity Directory

Reports

Browse All Reports 📰 News ⚖ Justice Monitor

Source

🏛 DOJ Production 📜 EFTA Law 📁 Source Data (GitHub) 🌐 Community Resources ✉ Contact
🎧 Podcast & Newsletter ❤️ Donate Privacy Policy

HOUSE_OVERSIGHT_025888

← Prev Next →
Loading document…

From: Sultan Bin Sulayern Sent: 7/24/2015 8:37:24 PM To: Jeffrey Epstein [[email protected]] Subject: Fwd: FDA Approved a Potent and Pricey Cholesterol lowering drug today Importance: — High Have you heard of this colestrol Jul 24, 2015 @ 3:23 PM 1,169 views The FDA Approves A Potent And Pricey Cholesterol-Lowering Shot Matthew Herper , Forbes Staff I cover science and medicine, and believe this is biology's century. ° Follow on Forbes (1970) ° Full Bio ° Recent Posts e Popular Posts I believe this is biology's century. I've covered science and medicine for Forbes from the Human Genome Project through Vioxx to the blossoming DNA technology changing the world today. Email me, follow me on Twitter, circle me onGoogle Plus, or subscribe to my Facebook page. Loading... Loading... The Food and Drug Administration has approved Praluent, a new medicine to lower cholesterol in people who have established heart disease, for people whose risk of a heart attack or stroke is not being adequately controlled by existing drugs called statins. It might be a big step in the battle against heart disease — and the approval is a triumph for Regeneron Pharmaceuticals, the Tarrytown, N.Y.-based biotechnology company that invented it. Praluent is likely to be more widely used, and to cost more, than Wall Steet analysts expected. That also means it could be a big cost down the line. “Obviously, the class is one of the biggest developments in cardiology in the last decade, that will allow us to treat patients who have been extremely difficult to treat with high levels of LDL cholesterol,” says Steven HOUSE_OVERSIGHT_025888

Suggest a category
Misclassified? Pick a better fit.
Community Notes
▸ People Mentioned
▸ Interest Level
Routine Notable Significant
▸ Dates Mentioned
▸ Related Topics
▸ Places & Organizations
▸ Transcription Correction
▸ Research Notes 0
No notes yet.
Related documents
Source Data Investigation Reports DOJ EFTA CC BY-NC-SA 4.0 Contact
Independent research project. Not affiliated with the U.S. Department of Justice, FBI, any government agency, or Anthropic. All analytical text on this site is AI-generated (Claude, Anthropic) and iteratively fact-checked against source documents, but may contain errors. Verify all claims against linked EFTA sources before citing.
Powered by Datasette  ·  ❤️ Buy me a coffee

You are leaving epstein-data.com

You are being redirected to an external website not operated by this project. We are not responsible for the content or privacy practices of external sites.

Powered by Datasette